New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
December 16, 2024 - The FDA approved a label update to Astellas’ Veozah (fezolinetant), adding a Boxed Warning for the risk of hepatotoxicity.
Download PDF
Return to publications
